Giovanna Furneri, Simone Varrasi, Claudia Savia Guerrera, Giuseppe Alessio Platania, Vittoria Torre, Francesco Maria Boccaccio, Maria Federica Testa, Federica Martelli, Alessandra Privitera, Grazia Razza, Mario Santagati, Santo Di Nuovo, Concetta Pirrone, Sabrina Castellano, Filippo Caraci, Roberto Monastero
Current drugs for Alzheimer's Disease (AD), such as cholinesterase inhibitors (ChEIs), exert only symptomatic activity. Different psychometric tools are needed to assess cognitive and non-cognitive dimensions during pharmacological treatment. In this pilot study, we monitored 33 mild-AD patients treated with ChEIs. Specifically, we evaluated the effects of 6 months (Group 1 = 17 patients) and 9 months (Group 2 = 16 patients) of ChEIs administration on cognition with the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), and the Frontal Assessment Battery (FAB), while depressive symptoms were measured with the Hamilton Depression Rating Scale (HDRS)...
April 17, 2024: Aging Clinical and Experimental Research